BR112012006638A2 - hidratos de cloreto de metiltionínio cristalinos - Google Patents

hidratos de cloreto de metiltionínio cristalinos

Info

Publication number
BR112012006638A2
BR112012006638A2 BR112012006638A BR112012006638A BR112012006638A2 BR 112012006638 A2 BR112012006638 A2 BR 112012006638A2 BR 112012006638 A BR112012006638 A BR 112012006638A BR 112012006638 A BR112012006638 A BR 112012006638A BR 112012006638 A2 BR112012006638 A2 BR 112012006638A2
Authority
BR
Brazil
Prior art keywords
methylthioninium chloride
chloride hydrates
crystalline methylthioninium
crystalline
hydrates
Prior art date
Application number
BR112012006638A
Other languages
English (en)
Other versions
BR112012006638B1 (pt
Inventor
Rolf Hilfiker
Timo Rager
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43415329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012006638(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Priority to BR122019022631A priority Critical patent/BR122019022631B8/pt
Priority to BR122019022628A priority patent/BR122019022628B8/pt
Priority to BR122019022612A priority patent/BR122019022612B8/pt
Publication of BR112012006638A2 publication Critical patent/BR112012006638A2/pt
Publication of BR112012006638B1 publication Critical patent/BR112012006638B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4515Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/22[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BR112012006638-2A 2009-09-24 2010-09-23 Forma c de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica BR112012006638B1 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR122019022631A BR122019022631B8 (pt) 2009-09-24 2010-09-23 forma d de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
BR122019022628A BR122019022628B8 (pt) 2009-09-24 2010-09-23 forma b de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
BR122019022612A BR122019022612B8 (pt) 2009-09-24 2010-09-23 forma e de mono-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24539109P 2009-09-24 2009-09-24
US61/245,391 2009-09-24
PCT/IB2010/002526 WO2011036558A2 (en) 2009-09-24 2010-09-23 Crystalline methylthionium chloride (methylene blue) hydrates

Publications (2)

Publication Number Publication Date
BR112012006638A2 true BR112012006638A2 (pt) 2016-05-03
BR112012006638B1 BR112012006638B1 (pt) 2020-05-26

Family

ID=43415329

Family Applications (4)

Application Number Title Priority Date Filing Date
BR122019022631A BR122019022631B8 (pt) 2009-09-24 2010-09-23 forma d de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
BR112012006638-2A BR112012006638B1 (pt) 2009-09-24 2010-09-23 Forma c de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
BR122019022612A BR122019022612B8 (pt) 2009-09-24 2010-09-23 forma e de mono-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
BR122019022628A BR122019022628B8 (pt) 2009-09-24 2010-09-23 forma b de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019022631A BR122019022631B8 (pt) 2009-09-24 2010-09-23 forma d de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122019022612A BR122019022612B8 (pt) 2009-09-24 2010-09-23 forma e de mono-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
BR122019022628A BR122019022628B8 (pt) 2009-09-24 2010-09-23 forma b de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica

Country Status (20)

Country Link
US (1) US8765742B2 (pt)
EP (4) EP3378856B1 (pt)
JP (1) JP5806217B2 (pt)
KR (3) KR20170061177A (pt)
CN (2) CN102666511B (pt)
AU (1) AU2010299571B2 (pt)
BR (4) BR122019022631B8 (pt)
CA (4) CA3141737C (pt)
DK (4) DK2963024T3 (pt)
ES (4) ES2689029T3 (pt)
FI (1) FI3792254T3 (pt)
HK (2) HK1167653A1 (pt)
HR (3) HRP20181567T2 (pt)
MX (2) MX2012003083A (pt)
MY (1) MY159782A (pt)
PL (4) PL2480541T3 (pt)
PT (4) PT2480541E (pt)
SG (1) SG10201408584UA (pt)
SI (4) SI2963024T1 (pt)
WO (1) WO2011036558A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2480540B1 (en) * 2009-09-24 2017-11-29 WisTa Laboratories Ltd. Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP3563849A3 (en) * 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
MY201804A (en) 2016-07-25 2024-03-19 Wista Laboratories Ltd Administration and dosage of diaminophenothiazines
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
CN104119294B (zh) * 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN103735554B (zh) 2006-03-29 2018-03-20 维斯塔实验室有限公司 蛋白聚集抑制剂
CN101631780A (zh) * 2007-04-03 2010-01-20 普罗瑟塔生物谐成公司 用于抗病毒治疗的吩噻嗪衍生物
US7603854B2 (en) 2007-04-10 2009-10-20 Illinois Tool Works Inc. Pneumatically self-regulating valve

Also Published As

Publication number Publication date
EP2963024A2 (en) 2016-01-06
EP3378856B1 (en) 2020-12-02
CA3077911C (en) 2022-03-01
SG10201408584UA (en) 2015-02-27
MY159782A (en) 2017-01-31
KR20170061177A (ko) 2017-06-02
KR20120099409A (ko) 2012-09-10
DK3792254T3 (da) 2023-09-25
HK1167653A1 (en) 2012-12-07
MX2012003083A (es) 2012-04-30
SI2480541T1 (sl) 2016-02-29
DK2480541T3 (en) 2016-02-01
HRP20210086T1 (hr) 2021-03-05
WO2011036558A9 (en) 2011-08-04
US20120238556A1 (en) 2012-09-20
PL3378856T3 (pl) 2021-05-31
FI3792254T3 (fi) 2023-09-22
CA3077911A1 (en) 2011-03-31
US8765742B2 (en) 2014-07-01
CA2773305C (en) 2018-07-03
EP2963024A3 (en) 2016-02-17
ES2557318T3 (es) 2016-01-25
JP5806217B2 (ja) 2015-11-10
ES2689029T3 (es) 2018-11-08
AU2010299571A1 (en) 2012-04-12
HK1213897A1 (zh) 2016-07-15
PL2480541T3 (pl) 2016-03-31
WO2011036558A2 (en) 2011-03-31
BR122019022612B8 (pt) 2021-07-27
EP3378856A2 (en) 2018-09-26
PT3378856T (pt) 2021-02-02
CA3004822A1 (en) 2011-03-31
EP2480541B1 (en) 2015-11-04
EP3792254B1 (en) 2023-07-26
WO2011036558A3 (en) 2011-11-24
JP2013505925A (ja) 2013-02-21
PT2480541E (pt) 2016-01-26
BR122019022631B1 (pt) 2021-03-16
HRP20181567T2 (hr) 2022-09-30
PL2963024T3 (pl) 2019-02-28
ES2960761T3 (es) 2024-03-06
CA3004822C (en) 2020-07-21
SI2963024T1 (sl) 2018-10-30
BR122019022631B8 (pt) 2021-07-27
DK3378856T3 (da) 2020-12-21
PL3792254T3 (pl) 2024-02-12
CN102666511A (zh) 2012-09-12
SI3378856T1 (sl) 2021-03-31
EP2963024B1 (en) 2018-07-18
AU2010299571B2 (en) 2014-07-31
PT2963024T (pt) 2018-10-16
CN105061358A (zh) 2015-11-18
BR122019022612B1 (pt) 2021-03-09
EP3792254A1 (en) 2021-03-17
CA3141737A1 (en) 2011-03-31
BR112012006638B1 (pt) 2020-05-26
MX355627B (es) 2018-04-25
HRP20231201T1 (hr) 2024-01-19
CA3141737C (en) 2023-10-03
CN102666511B (zh) 2015-09-16
EP3378856A3 (en) 2018-11-07
CA2773305A1 (en) 2011-03-31
DK2963024T3 (en) 2018-10-08
BR122019022628B1 (pt) 2021-03-16
BR122019022628B8 (pt) 2021-07-27
KR20180094126A (ko) 2018-08-22
SI3792254T1 (sl) 2023-11-30
EP2480541A2 (en) 2012-08-01
PT3792254T (pt) 2023-10-19
ES2847003T3 (es) 2021-07-30
HRP20181567T1 (hr) 2018-11-30

Similar Documents

Publication Publication Date Title
NO2021013I1 (no) filgotinib or a salt thereof
LTPA2018008I1 (lt) Kristalai
CY2017026I1 (el) Τετρακυκλικη ενωση
SMT201600008B (it) Composti di piridazinone
BR112012006638A2 (pt) hidratos de cloreto de metiltionínio cristalinos
BR112012006859A2 (pt) compostos
DK2427449T3 (da) Vinylindazolylforbindelser
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BRPI1008774A2 (pt) espiroamida substituída
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI1013868A2 (pt) composto diaciletilenodiamina
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
BR112012004964A2 (pt) girocóptero
BR112012000657A2 (pt) novos azabicilohexanos
BRPI1008070A2 (pt) tricianoboratos
UY33156A (es) Nuevos compuestos tienopirrol
BRPI1010159A2 (pt) bistuti
BR112013002589A2 (pt) valsatana altamente cristalina
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
BRPI1009199A2 (pt) compostos de pirazinoisoquinolina
FI20095440A (fi) Muodostusosa
BRPI1014080A2 (pt) Compostos substituidos de enaminocarbolina
DE102009038881A8 (de) Geräteeinheit
AT506924A3 (de) Bauprojektor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: WISTA LABORATORIES LTD. (SG)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/09/2010, OBSERVADAS AS CONDICOES LEGAIS.